Abstract
An enzyme immunoassay for prostatic acid phosphatase (PAP) has been assessed. An upper limit of normal is set at 1.8 μg/1. There is a very low incidence of raised levels in chronic disease or cancers other than those of the prostate. Patients with well-controlled prostatic cancer have levels < 1.8 μg/1 and show little variation about their own mean. PAP can rise exponentially with a doubling time of 1–5 months. This assay is unlikely to increase the detection of asymptomatic prostatic cancer as 66% of T 0–2N xM 0 cases had PAP < 1.8 μg/l. The main advantages over routine enzyme assays are its sensitivity and accuracy in the lower range.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call